Do you want to contribute to improving human health?

The tumor suppressor gene TP53 is the most frequently mutated gene in cancer. We perform world-leading research in the area of therapeutic targeting of tumors with dysfunctional mutant p53 protein. We are focusing on the role of dysfunctional p53 in leukemia and clonal hematopoiesis, and the postdoctoral candidate will use state-of-the-art technologies to examine p53 conformation and the transcriptome at the single cell level.

Your mission

This postdoctoral position is focused on the development of novel technology for studying the conformation of the p53 protein and the transcriptome at the single cell level. The candidate will study the molecular functional consequences, i.e. transcriptional impact, of misfolded p53 (PMp53) in conditions that precede AML and carry a wildtype TP53 gene. The candidate will also test the ability of the mutant p53-targeting compound APR-246 and other compounds with similar activity to modulate the conformational state of PMp53 and thereby eliminate malignant or pre-malignant cells. This research is based on our experience with p53-targeted therapy and insights from the molecular mechanisms of action of APR-246. The generated data will allow the design of biomarker-guided preclinical and clinical studies for AML screening and prevention.

Your profile

To be eligible for employment as a postdoctor a doctoral degree or a foreign degree deemed to be equivalent to a doctoral degree is required. This eligibility requirement must be fulfilled at the latest at the time of the employment decision. It is considered as an advantage if you have completed your doctoral degree within the last three years, if there are special reasons, your degree may have been completed earlier.

For this postdoctoral position we are particularly interested in recruiting a person with strong competence in hematology and hematological malignancies and previous knowledge and experience with the tumor suppressor p53. An MD degree and clinical experience in hematology are strong assets.

What do we offer?

A creative and inspiring environment with wide-ranging expertise and interests. Karolinska Institutet is one of the world's leading medical universities. At Karolinska Institutet, we conduct successful medical research and hold the largest range of medical education in Sweden. At KI, you get to meet researchers working with a wide range of specialisms and methods, giving you ample opportunity to exchange knowledge and experience with the various scientific fields within medicine and health. It is the crossover collaborations, which have pushed KI to where it is today, at the forefront of global research. Several of the people you meet in healthcare are educated at KI. A close relationship with the health care providers is important for creating groundbreaking top quality education and research. Karolinska Institutet is also a state university, which entitles you to several benefits through our collective agreement.

Dept. of Oncology-Pathology, Karolinska Institutet, Bioclinicum, Solna

Choose to work at KI – Ten reasons why


An employment application must contain the following documents in English or Swedish:

  • A complete resumé, including date of the thesis defence, title of the thesis, previous academic positions, academic title, current position, academic distinctions, and committee work
  • A complete list of publications
  • A summary of current work (no more than one page)

Welcome to apply at the latest 19th June. 

The application is to be submitted through the Varbi recruitment system.

The position is for 2 years. With possibility of extension 1+1 year. 

Want to make a difference? Join us and contribute to better health for all

Type of employment Temporary position
Contract type Full time
First day of employment Up on agreement
Salary Monthly sallary
Number of positions 1
Full-time equivalent 100 %
City Solna
County Stockholms län
Country Sweden
Reference number STÖD 2-2231/2023
  • Klas Wiman,
Union representative
  • Helen Eriksson, OFR,
  • Henry Wölling, Seko,
  • Per Hydbring/Nick Tobin, Saco,
Published 29.May.2023
Last application date 19.Jun.2023 11:59 PM CEST

Return to job vacancies